Genmab A/S (GMAB)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Genmab A/S (GMAB) is down 16.9% since the beginning of the year. At $26 per share, GMAB is trading 27.7% below its 52-week high of $35. Investors who bought $1,000 worth of GMAB shares 5 years ago would now be looking at an investment worth $612.

Genmab A/S (GMAB) has returned -16.85% so far this year and 21.03% over the past 12 months. Over the last ten years, GMAB has returned 4.44% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Jun 1, 2009, GMAB's average daily return is +0.09%, while the average monthly return is +1.77%. At this rate, an investment would double in approximately 3.3 years.

Historically, 49% of months were positive and 51% were negative. The best month was Jul 2012 with a return of +56.0%, while the worst month was Aug 2011 at -51.6%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 6 months.

On a daily basis, GMAB closed higher 37% of trading days. The best single day was Jul 24, 2012 with a return of +57.5%, while the worst single day was Aug 8, 2011 at -51.6%.

Genmab A/S has an annualized alpha of 13.33%, beta of 0.66, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since June 01, 2009.

• This stock participated in 91.05% of S&P 500 Index downside but only 88.49% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.66 may look defensive, but with R2 of 0.07 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

GMAB ranks 58 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Genmab A/S. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Genmab A/S was 84.20%, occurring on Aug 8, 2011. Recovery took 538 trading sessions.

The current Genmab A/S drawdown is 47.43%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Genmab A/S over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Genmab A/S is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.